Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study

Oncogenic ROS1 and NTRK fusions were reported in solid tumors, including non-small cell lung cancer (NSCLC). DS-6051b is an oral, potent selective small molecule tyrosine kinase inhibitor. We report the safety, tolerability, efficacy, and pharmacokinetics of DS-6051b in 15 Japanese patients with NSC...

Descripción completa

Detalles Bibliográficos
Autores principales: Fujiwara, Yutaka, Takeda, Masayuki, Yamamoto, Noboru, Nakagawa, Kazuhiko, Nosaki, Kaname, Toyozawa, Ryo, Abe, Chihiro, Shiga, Ryota, Nakamaru, Kenji, Seto, Takashi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955103/
https://www.ncbi.nlm.nih.gov/pubmed/29805770
http://dx.doi.org/10.18632/oncotarget.25263

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955103/
https://www.ncbi.nlm.nih.gov/pubmed/29805770
http://dx.doi.org/10.18632/oncotarget.25263

Ejemplares similares